Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083

By sjmartinez • November 24, 2024

Clement ME, Hanscom B, Haines D, Bazan JA, Chotirosniramit N, Kofron R, Mannheimer S, Mayer KH, Torres Silva MS, Soto-Torres L, Rinehart AR, Rooney JF, Jennings A, Gomez-Feliciano K, McCauley M, Grinsztejn B, Landovitz RJ; for HPTN 083 Study Team. Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083. Clin Infect Dis. 2024 Nov 23:ciae572. doi: 10.1093/cid/ciae572. Epub ahead of print. PMID: 39579334.

Tags: bacterial sexually transmitted infections, CAB-LA, efficacy, HIV prevention, Infectious Diseases, Long-acting PrEP, Publications

Maternal and neonatal outcomes after infection with monkeypox virus clade I during pregnancy in DR Congo: a pooled, prospective cohort study

Vakaniaki EH, Barhishindi I, Mubiala A, Malembaka EB, Braunack-Mayer L, Nganga B, Sabiti Nundu S, Brosius I, Bracke S, Bangwen E, De Vos E, Colebunders[...]

Timeliness of yellow fever specimen collection and transport in Ghana, 2018-2022

Judson SD, Schroeder L, Asiedu-Bekoe F, Laryea DO, Boateng G, Gudjinu H, Ossom R, Danquah JF, Dowdy DW, Kenu E. Timeliness of yellow fever specimen[...]

Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden[...]